Celebrating the grand opening of its cutting-edge radiopharmaceutical production facility in Hamilton, AtomVie aims to enhance cancer treatment globally.

AtomVie and TerraPower have formed a strategic partnership for high-quality Actinium-225 supply to advance radiopharmaceutical development and improve patient outcomes globally.

HAMILTON — Ontario’s life sciences sector is receiving a major lift as AtomVie Global Radiopharma Inc. announces a $138-million expansion of its Hamilton

AtomVie celebrates the grand opening of a state-of-the-art radiopharmaceutical manufacturing facility in Hamilton, Ontario, enhancing global healthcare.

HAMILTON, ONTARIO, 7. September 2026 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), eine weltweit führende Contract Development and Manufacturing Organization (CDMO) in der Radiopharmazie, feierte heute die feierliche Eröffnung seiner neuen, eigens für diesen Zweck errichteten und...

HAMILTON, ONTARIO, 7 septembre 2026 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), une organisation de développement et de fabrication sous contrat (CDMO) de premier plan à l'échelle mondiale dans le secteur des radiopharmaceutiques, a célébré aujourd'hui l'inauguration officielle...

AtomVie Global Radiopharma (AtomVie), a leading global Contract Development and Manufacturing Organization (CDMO) in the radiopharmaceutical industry,

AtomVie Global Radiopharma has inaugurated its advanced radiopharmaceutical manufacturing facility in Hamilton, Ontario, enhancing production capabilities and patient care.

-AtomVie Global Radiopharma celebra la inauguración de sus nuevas instalaciones de fabricación de radiofármacos de última generación en Hamilton, Ontario HAMILTON, Ontario, 5 de septiembre de 2026 /PRNewswire/ - AtomVie Global Radiopharma (AtomVie), una organización líder a nivel mundial...

AtomVie Global Radiopharma marks a significant milestone with the grand opening of its new cutting-edge facility in Hamilton, Ontario, enhancing radiopharmaceutical production capabilities.

AtomVie Global Radiopharma recently inaugurated a state-of-the-art radiopharmaceutical manufacturing facility in Hamilton, Ontario, enhancing its capacity significantly.

HAMILTON, ON, Sept. 4, 2026 /PRNewswire/ - AtomVie Global Radiopharma (AtomVie), a leading global Contract Development and Manufacturing Organization (CDMO) in the radiopharmaceutical industry, today celebrated the Grand Opening of its new purpose-built, state-of-the-art manufacturing...

HAMILTON, ON, Sept. 4, 2026 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), a leading global Contract Development and Manufacturing Organization (CDMO) in the radiopharmaceutical industry, today celebrated the Grand Opening of its new purpose-built, state-of-the-art manufacturing...

Hamilton, Ontario--(Newsfile Corp. - April 9, 2026) - AtomVie Global Radiopharma (AtomVie), a global leading radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) specializing in GMP manufacturing for clinical and commercial supply of radiopharmaceuticals and their worldwide distribution, is pleased to announce that they will be presenting at the Bloom Burton & Co. Healthcare Investor Conference (BBHIC) 2026, taking place at the Metro Convention Centre in Toronto,...

BioNexus gets $500M for CDMO expansion; Thermo Fisher grows in Asia; AtomVie invests $138M in Ontario; FDA picks enGene's detalimogene for pilot; new partnerships form in biotech

The aim is to strengthen the supply chain and accelerate the development and commercialization of targeted radiopharmaceutical therapies for cancer and other diseases.

AtomVie Global Radiopharma has successfully supplied the first patient dose for the Phase 1/2a clinical study of 177Lu-BetaBart, marking a significant milestone in cancer therapy.

AtomVie Global Radiopharma celebrates a pivotal achievement in manufacturing by supplying the first patient dose in Radiopharm’s clinical trial for 177Lu-BetaBart.

AtomVie Global Radiopharma marks a vital achievement in cancer treatment with the successful dosing of the first patient in the 177Lu-BetaBart clinical trial, highlighting the progress in radiopharmaceutical development.

AtomVie Global Radiopharma marks a significant milestone by successfully administering the first patient dose in a Phase 1/2a clinical trial.

AtomVie Global Radiopharma has successfully provided the first dose in a critical Phase 1/2a clinical study for 177Lu-BetaBart, setting a significant milestone in radiopharmaceutical development.

This article discusses the strategic supply agreement between AtomVie Global Radiopharma and Ionetix Corporation to advance Ac-225 radiotherapy development.

This article details AtomVie Global Radiopharma's new partnership with Ionetix Corporation, aimed at enhancing Ac-225 radiopharmaceuticals' development.

AtomVie Global Radiopharma has secured a supply agreement with Ionetix Corporation, enhancing their access to critical radioisotopes for therapeutic development.